Bollard Group’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $52K | Hold |
277
| – | – | ﹤0.01% | 229 |
|
|
2026
Q1 | $55K | Hold |
277
| – | – | ﹤0.01% | 235 |
|
|
2025
Q4 | $51K | Sell |
277
-518
| -65% | -$90.8K | ﹤0.01% | 232 |
|
|
2025
Q3 | $122K | Buy |
795
+5
| +0.6% | +$757 | ﹤0.01% | 175 |
|
|
2025
Q2 | $110K | Buy |
790
+24
| +3% | +$3.36K | ﹤0.01% | 195 |
|
|
2025
Q1 | $113K | Buy |
766
+11
| +1% | +$1.59K | ﹤0.01% | 181 |
|
|
2024
Q4 | $99K | Hold |
755
| – | – | ﹤0.01% | 186 |
|
|
2024
Q3 | $118K | Buy |
755
+4
| +0.5% | +$646 | ﹤0.01% | 192 |
|
|
2024
Q2 | $117K | Hold |
751
| – | – | ﹤0.01% | 190 |
|
|
2024
Q1 | $102K | Buy |
751
+11
| +1% | +$1.46K | ﹤0.01% | 191 |
|
|
2023
Q4 | $100K | Hold |
740
| – | – | ﹤0.01% | 187 |
|
|
2023
Q3 | $100K | Buy |
740
+5
| +0.7% | +$683 | ﹤0.01% | 183 |
|
|
2023
Q2 | $105K | Buy |
735
+264
| +56% | +$38.8K | ﹤0.01% | 188 |
|
|
2023
Q1 | $65K | Buy |
471
+7
| +2% | +$942 | ﹤0.01% | 208 |
|
|
2022
Q4 | $63K | Hold |
464
| – | – | ﹤0.01% | 202 |
|
|
2022
Q3 | $51K | Buy |
464
+3
| +0.7% | +$381 | ﹤0.01% | 213 |
|
|
2022
Q2 | $61K | Hold |
461
| – | – | ﹤0.01% | 221 |
|
|
2022
Q1 | $61K | Buy |
461
+7
| +2% | +$839 | ﹤0.01% | 323 |
|
|
2021
Q4 | $53K | Hold |
454
| – | – | ﹤0.01% | 341 |
|
|
2021
Q3 | $54K | Buy |
+454
| New | +$52.8K | ﹤0.01% | 338 |
|
|
2019
Q3 | – | Sell |
-23,594
| Closed | -$1.95M | – | 234 |
|
|
2019
Q2 | $1.95M | Hold |
23,594
| – | – | 0.07% | 114 |
|
|
2019
Q1 | $1.91M | Buy |
23,594
+503
| +2% | +$39.6K | 0.07% | 112 |
|
|
2018
Q4 | $1.75M | Hold |
23,091
| – | – | 0.08% | 111 |
|
|
2018
Q3 | $1.83M | Buy |
23,091
+264
| +1% | +$20K | 0.07% | 110 |
|
|
2018
Q2 | $1.6M | Hold |
22,827
| – | – | 0.07% | 113 |
|
|
2018
Q1 | $1.6M | Buy |
22,827
+594
| +3% | +$41.1K | 0.08% | 115 |
|
|
2017
Q4 | $1.54M | Hold |
22,233
| – | – | 0.07% | 112 |
|
|
2017
Q3 | $1.51M | Buy |
22,233
+294
| +1% | +$18.6K | 0.08% | 119 |
|
|
2017
Q2 | $1.5M | Hold |
21,939
| – | – | 0.08% | 123 |
|
|
2017
Q1 | $1.37M | Buy |
21,939
+643
| +3% | +$37.4K | 0.08% | 123 |
|
|
2016
Q4 | $1.16M | Hold |
21,296
| – | – | 0.08% | 129 |
|
|
2016
Q3 | $1.4M | Buy |
21,296
+284
| +1% | +$18.6K | 0.09% | 116 |
|
|
2016
Q2 | $1.27M | Buy |
21,012
+1,025
| +5% | +$59.5K | 0.09% | 116 |
|
|
2016
Q1 | $1.13M | Buy |
19,987
+635
| +3% | +$38.2K | 0.09% | 118 |
|
|
2015
Q4 | $1.31M | Hold |
19,352
| – | – | 0.11% | 108 |
|
|
2015
Q3 | $1.23M | Buy |
19,352
+3,327
| +21% | +$219K | 0.1% | 121 |
|
|
2015
Q2 | $1.02M | Hold |
16,025
| – | – | 0.08% | 138 |
|
|
2015
Q1 | $1.1M | Buy |
16,025
+9,225
| +136% | +$641K | 0.08% | 131 |
|
|
2014
Q4 | $479K | Buy |
+6,800
| New | +$487K | 0.04% | 154 |
|
Other funds holding AZN
EP
IA
Bollard Group's AZN Position: Q2 2026 in Review
Bollard Group held its AstraZeneca (AZN) position steady in Q2 2026 at 277 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #229.
Bollard Group first reported a position in AZN in Q4 2014 and has held it in 39 quarters since. The position peaked at $1.95M in Q2 2019. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Bollard Group held 277 shares of AstraZeneca worth $52K as of Q2 2026.
- Bollard Group left its AstraZeneca share count unchanged in Q2 2026.
- AstraZeneca made up ﹤0.01% of Bollard Group's portfolio in Q2 2026, its #229 holding.
- Bollard Group first reported a position in AstraZeneca in Q4 2014 and has held it in 39 quarters since.
- Bollard Group's AstraZeneca position peaked at $1.95M in Q2 2019.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.